Karyopharm announces ongoing phase 3 siendo study of xpovio® (selinexor) in patients with endometrial cancer passes planned interim futility analysis: data and safety monitoring board recommends the study should proceed as planned without any modifications

Newton, mass., nov. 25, 2020 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq: kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that following a pre-specified interim futility analysis for the ongoing phase 3 siendo study, the data...
KPTI Ratings Summary
KPTI Quant Ranking